Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × tislelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 25 Carcinoma, Hepatocellular 22 Colorectal Neoplasms 16 Stomach Neoplasms 13 Esophageal Squamous Cell Carcinoma 13 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 8 Head and Neck Neoplasms 8 Cholangiocarcinoma 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 6 Nasopharyngeal Carcinoma 6 Rectal Neoplasms 5 Recurrence 4 Pancreatic Neoplasms 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4 Colonic Neoplasms 4 Neoplasms 3 NSCLC 3 Lymphoma, Extranodal NK-T-Cell 3 Glioblastoma 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Melanoma 2 Lymphoma, Follicular 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡